Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
PATHEON INC (PTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/11/2014 8-K Quarterly results
03/10/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "PATHEON INC. ANNOUNCES FINAL COURT APPROVAL OF ARRANGEMENT"
03/06/2014 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "PATHEON SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT"
03/06/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Patheon Reports Preliminary Unaudited First Quarter Fiscal 2014 Results TORONTO, March 6, 2014 /CNW/ - Patheon Inc. , a leading provider of contract development and manufacturing services to the global pharmaceutical industry, with recently acquired proprietary products, announced today preliminary unaudited fiscal 2014 first-quarter results. Based on its current expectations, Patheon anticipates the following results for its first-quarter ended January 31, 2014: • Revenues of approximately $266.7 million versus $213.5 million in the prior year. • Adjusted EBITDA of approximately $36.4 million versus $19.8 million in the prior year. • Loss from continuing operations of approximately $0.1 million versus a loss of $51.4 million in the prior year. Because Patheon's results of operations for t..."
02/25/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "LEADING INDEPENDENT ADVISORY FIRM ISS RECOMMENDS IN FAVOUR OF THE ARRANGEMENT INVOLVING PATHEON INC."
02/04/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Patheon Inc. Files Proxy Statement for Special Meeting of Shareholders"
01/10/2014 8-K Quarterly results
Docs: "PATHEON REPORTS FISCAL 2013 RESULTS"
01/07/2014 8-K Results of Operations and Financial Condition
12/20/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/03/2013 8-K Form 8-K - Current report
09/05/2013 8-K Investor presentation, Quarterly results
Docs: "PATHEON REPORTS FISCAL 2013 THIRD QUARTER RESULTS",
"Presentation for the Company's conference call on September 5, 2013"
06/03/2013 8-K Investor presentation
Docs: "PATHEON REPORTS FISCAL 2013 SECOND QUARTER RESULTS",
"Presentation for the Company's conference call on June 3, 2013"
05/21/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2013 8-K Investor presentation, Quarterly results
Docs: "PATHEON REPORTS FISCAL 2013 FIRST QUARTER RESULTS",
"Presentation for the Company's conference call on March 8, 2013"
03/01/2013 8-K/A Financial Statements and Exhibits
Docs: "Consent of Smith Leonard PLLC",
"Consent of BDO Audit & Assurance B.V",
"Unaudited pro forma combined financial information of Patheon Inc"
01/11/2013 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/03/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Patheon Inc. Successfully Completes Rights Offering TORONTO, CANADA - December 31, 2012 - Patheon Inc. , a leading provider of manufacturing and contract development services to the global pharmaceutical industry, today announced the completion of its subscription rights offering, which expired on December 28, 2012. The rights offering was fully subscribed for with gross proceeds totaling approximately US$30 Million. Effective today, Patheon will issue 9,403,483 restricted voting shares as a result of the rights offering. This issuance represents approximately 7.2% of the Company's restricted voting shares issued and outstanding prior to the rights offering. Upon the issuance of these new restricted voting shares, the Company will have 139,701,375 restricted voting shares outstanding. An a..."
12/17/2012 8-K Form 8-K - Current report
12/17/2012 8-K Form 8-K - Current report
12/03/2012 8-K/A Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Information provided to lenders"
11/19/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Form of Subscription Rights Certificate",
"Opinion of Fraser Milner Casgrain LLP"
11/19/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Press Release"
11/19/2012 8-K Financial Statements and Exhibits
Docs: "Consent of Smith Leonard PLLC",
"Consent of BDO Audit & Assurance B.V",
"Audited consolidated financial statements of Sobel USA as of December 31, 2011 and 2010 and for each of the years then ended",
"Audited consolidated financial statements of Sobel USA as of December 31, 2010 and 2009 and for each of the years then ended",
"Unaudited consolidated financial statements of Sobel USA as of September 30, 2012 and December 31, 2011 and for the nine months ended September 30, 2012 and 2011",
"Audited financial statements of Banner Europe as of December 31, 2011 and 2010 and for each of the years then ended",
"Audited financial statements of Banner Europe as of December 31, 2010 and 2009 and for each of the years then ended",
"Unaudited financial statements of Banner Europe as of September 30, 2012 and December 31, 2011 and for the nine months ended September 30, 2012 and 2011",
"Unaudited pro forma condensed combined financial information of the Company"
10/29/2012 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financia...
Docs: "Stock Purchase Agreement by and among Sobel Best N.V., Vion Holding N.V. and Patheon Inc.",
"Commitment Letter by and among Morgan Stanley Senior Funding, Inc., UBS Loan Finance LLC, UBS Securities LLC, Credit Suisse AG, Credit Suisse Securities (USA) LLC, KeyBank National Association and Patheon Inc.",
"Equity Commitment Letter between JLL Partners V, L.P. and Patheon Inc.",
"Patheon to Acquire Banner Pharmacaps",
"Patheon Announces Refinancing in Connection with Acquisition of Banner Pharmacaps",
"Presentation for the Company's conference call on October 29, 2012"
08/17/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Patheon Announces a Change to its PDS Management Structure TORONTO, — Patheon Inc. , a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that Mark J. Kontny, Ph.D., President, Global Pharmaceutical Development Services and Chief Scientific Officer, is no longer with the company, effective as of this date. Until a replacement has been appointed, Dr. Kontny's duties will be managed by Patheon's existing PDS operations team. About Patheon Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Its ..."
06/13/2012 8-K Investor presentation
Docs: "PATHEON REPORTS FISCAL 2012 SECOND QUARTER RESULTS",
"Presentation for the Company's conference call on June 13, 2012"
05/09/2012 8-K Cost Associated with Exit or Disposal Activities, Material Impairments
03/27/2012 8-K Form 8-K - Current report
03/09/2012 8-K Investor presentation, Quarterly results
Docs: "PATHEON REPORTS FISCAL 2012 FIRST QUARTER RESULTS",
"Presentation for the Company's conference call on March 9, 2012"
02/15/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "STUART GRANT APPOINTED PATHEON'S EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER TORONTO, CANADA - Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Stuart Grant has been appointed Patheon's Executive Vice President, Chief Financial Officer. Mr. Grant comes to Patheon following an accomplished career with increasing levels of responsibility in finance for several successful, global public companies. “I am very pleased that Stuart has agreed to join the Patheon team,” stated Jim Mullen, Patheon's Chief Executive Officer. “He is a proven leader and respected financial executive who will be a key player in Patheon's transformation. I look forward to the many contributions he will make as we continue to ..."
12/19/2011 8-K Form 8-K - Current report
11/04/2011 8-K Form 8-K - Current report
10/06/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting and Separation Agreement between Patheon Pharmaceuticals Services Inc. and Peter T. Bigelow",
"PETER T. BIGELOW TO LEAVE PATHEON TORONTO, - Patheon, Inc. , a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Peter T. Bigelow, Patheon's President North American Operations, will leave the company effective November 1, 2011 to pursue new opportunities. “Patheon has benefited immensely from Peter's leadership and is pleased to announce that Peter has agreed to enter into a consulting relationship with the company for a certain period of time to ensure a smooth transition as we continue to focus on the transformation,” said Jim Mullen, Patheon's CEO. “We wish him great success with his future endeavors.” In commenting on the announcement, Mr. Bigelow said, “I am very proud of what we have accomplished at Pathe..."
09/09/2011 8-K Investor presentation, Quarterly results
Docs: "PATHEON REPORTS THIRD QUARTER FISCAL 2011 RESULTS Announces implementation of new corporate strategy TORONTO - Patheon Inc. , a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today:",
"Presentation for the Company's conference call on September 9, 2011"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy